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OBJECTIVES This study examined the hypothesis that patients who develop angiotensin-converting
enzyme inhibitor intolerance attributable to circulatory-renal limitations (CRLimit) have
more severe underlying disease and worse outcome.
BACKGROUND Although the renin-angiotensin system contributes to the progression of heart failure (HF),
it also supports the failing circulation. Patients with the most severe disease may not tolerate
inhibition of this system.
METHODS Consecutive inpatient admissions to the cardiomyopathy service of the Brigham and
Women’s Hospital between 2000 and 2002 were reviewed retrospectively for initial profiles,
discharge medications, and documented reasons for discontinuation of angiotensin-
converting enzyme inhibitors. Outcomes of death and transplantation were determined.
RESULTS Of the 259 patients, 86 were not on an angiotensin-converting enzyme inhibitor at discharge.
Circulatory-renal limitations of symptomatic hypotension, progressive renal dysfunction, or
hyperkalemia were documented in 60 patients (23%); other adverse effects, including cough,
in 24 patients; and absent reasons in 2 patients. Compared with patients on angiotensin-
converting enzyme inhibitors, patients with CRLimit were older (60 vs. 55 years; p 0.006),
with longer history of HF (5 vs. 2 years; p 0.009), lower systolic blood pressure (104 vs. 110
mm Hg; p  0.05), lower sodium (135 vs. 138 mEql/l; p  0.002), and higher initial
creatinine (2.5 vs. 1.2 mg/dl; p  0.0001). Mortality was 57% in patients with CRLimit and
22% in the patients on angiotensin-converting enzyme inhibitors during a median 8.5-month
follow-up (p  0.0001).
CONCLUSIONS Development of CRLimit to angiotensin-converting enzyme inhibitor intolerance identifies
patients with severe disease who are likely to die during the next year. New treatment
strategies should be targeted to this population. (J Am Coll Cardiol 2003;41:2029–35)
© 2003 by the American College of Cardiology Foundation
Angiotensin-converting enzyme inhibitors decrease disease
progression and mortality from left ventricular dysfunction
(1–5). Therapy with angiotensin-converting enzyme inhib-
itors is recommended for all patients with heart failure (HF)
and reduced ejection fraction (6). The prevalence of
angiotensin-converting enzyme inhibitor administration
among patients with HF has been reported as 24% to 86%
(7–14). Angiotensin-converting enzyme inhibitor intoler-
ance is generally considered to be in the range of 8% to 15%
(15–18). From large trials conducted after angiotensin-
converting enzyme inhibitor therapy became standard prac-
tice, it has been estimated that 90% to 95% of such patients
will be on angiotensin-converting enzyme inhibitors (19–
21).
In normal circulation, the renin-angiotensin system sup-
ports blood pressure and renal perfusion via angiotensin-II
mediated vasoconstriction in the periphery and efferent
renal arterioles, potentiation of sympathetic stimulation,
and aldosterone release. Prolonged stimulation of this sys-
tem contributes to deleterious cardiovascular remodeling
that has been ameliorated by inhibition of components of
the renin-angiotensin system. Despite these advances, HF
remains a progressive disease. As circulation becomes in-
creasingly impaired, the renin-angiotensin system may be-
come indispensable for maintenance of blood pressure, renal
perfusion, and glomerular filtration (22). Thus, the progres-
sion to more advanced HF may be characterized by devel-
opment of a higher rate of angiotensin-converting enzyme
inhibitor nonuse than seen in previous populations.
This study examines angiotensin-converting enzyme in-
hibitor discontinuation and outcomes among patients hos-
pitalized with symptomatic HF and reduced ejection frac-
tion, with hypotheses: 1) a lower rate of angiotensin-
converting enzyme inhibitor prescription at discharge than
current standards may occur in advanced HF, owing to
circulatory-renal limitations (CRLimit) of symptomatic hy-
potension, progressive renal dysfunction, or hyperkalemia;
and 2) patients previously on angiotensin-converting en-
zyme inhibitors in whom angiotensin-converting enzyme
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inhibitors are discontinued because of circulatory or renal
limitations have more severe underlying disease and worse
outcome.
METHODS
Study population. The study population comprised con-
secutive patients followed by the Cardiomyopathy Service of
the Brigham and Women’s Hospital for whom HF dis-
charge information was recorded between 2000 and 2002.
For patients admitted more than once during this period,
data from their most recent hospitalization were collected.
Patients were excluded if the left ventricular ejection frac-
tion was 45%, or if death, cardiac transplantation, or
placement of a permanent mechanical circulatory device
occurred during hospitalization.
Data collection. Data were abstracted from hospital and
outpatient medical records. Establishment of reasons for
angiotensin-converting enzyme inhibitor nonuse relied ex-
clusively on explicit written documentation in the progress
notes of the reason for angiotensin-converting enzyme
inhibitor nonuse. No assumptions were based on the pa-
tient’s clinical status or laboratory data. Because all patients
not on angiotensin-converting enzyme inhibitors at hospital
discharge had undergone previous therapy with
angiotensin-converting enzyme inhibitors either during or
before hospitalization, the timing and location of
angiotensin-converting enzyme inhibitor discontinuation
were also recorded.
Demographic information, clinical characteristics during
hospitalization, and therapies on discharge were collected.
Baseline clinical descriptors included duration of HF by
either symptoms or known reduced left ventricular ejection
fraction, and New York Heart Association (NYHA) func-
tional class before hospitalization (as noted in the ambula-
tory record by the outpatient cardiologist or in the admis-
sion note as the baseline functional status before the
symptoms precipitating hospitalization). Heart rate and
blood pressure were recorded on admission and discharge;
electrocardiographic rhythm on admission; serum sodium
concentration on admission, discharge, and the lowest value
during hospitalization; and serum creatinine concentration
on admission, discharge, and the highest value during
hospitalization.
Follow-up. Death, cardiac transplantation, and placement
of a left ventricular assist device (LVAD) at the Brigham
and Women’s Hospital were collected between January and
April of 2002 with a median 8.5-month follow-up. To
ensure that deaths not occurring at the Brigham and
Women’s Hospital would be recorded, information was also
collected from the Social Security Death Index. Approval
for this study was obtained from the Institutional Review
Board of the Brigham and Women’s Hospital.
Determination of angiotensin-converting enzyme inhib-
itor use. Patients were divided into groups based on the
presence or absence of an angiotensin-converting enzyme
inhibitor among the medications prescribed at hospital
discharge. Patients not receiving angiotensin-converting
enzyme inhibitors at hospital discharge were then grouped
on the basis of the reasons for nonuse as documented in the
medical record: CRLimit (symptomatic hypotension, pro-
gressive renal insufficiency, or hyperkalemia), adverse effects
(cough-other; all other reasons), and unable to be deter-
mined from the written record. Patients exhibiting side
effects of both CRLimit and adverse effects were analyzed as
part of the CRLimit group. The two patients with unknown
reasons for angiotensin-converting enzyme inhibitor nonuse
were excluded from the subsequent analysis.
Statistical analysis. Continuous variables were summa-
rized by the median and quartiles and groups were com-
pared using the Wilcoxon rank sum test. Categorical vari-
ables were summarized by proportions and compared using
Fisher’s exact test. Product-limit methods were used for
time to event (death, cardiac transplantation, or LVAD
placement), and groups were compared using the log-rank
test. A multiple variable Cox proportional hazards model
was developed to assess the impact of CRLimit relative to
angiotensin-converting enzyme inhibitors for time to event
after controlling for age, ejection fraction, presence of
coronary artery disease, systolic blood pressure, sodium, and
creatinine. The criterion for entry and removal was 0.10 and
all selection methods resulted in the same final model.
SAS/STAT software was used (version 8.2, SAS Institute
Inc., Cary, North Carolina).
RESULTS
Study populations. Of the 316 patients followed, 57 pa-
tients were excluded because of ejection fraction 45%, or
end points during hospitalization. The remaining 259 pa-
tients comprise a population with advanced HF, evidenced
by median ejection fraction of 22%, 59% with NYHA class
III to IV HF at baseline before hospitalization.
Angiotensin-converting enzyme use and discontinuation.
Of the 259 patients in the study population, 86 (33%) were
not on an angiotensin-converting enzyme inhibitor at hos-
pital discharge (Table 1). There were 60 patients with
CRLimit to angiotensin-converting enzyme inhibitors (the
CRLimit group), the majority with progressive renal insuf-
ficiency and symptomatic hypotension, and 24 with other
effects (the cough-other group), primarily cough. Reasons
for angiotensin-converting enzyme inhibitor nonuse were
explicitly documented in the medical records for all except
two patients, who were excluded from the subsequent
Abbreviations and Acronyms
CRLimit  circulatory-renal limitations
HF  heart failure
LVAD  left ventricular assist device
NYHA  New York Heart Association
SBP  systolic blood pressure
2030 Kittleson et al. JACC Vol. 41, No. 11, 2003
CRLimit to Angiotensin-Converting Enzyme Inhibitors June 4, 2003:2029–35
analysis. All of the remaining 84 patients had previously
been on an angiotensin-converting enzyme inhibitor.
The angiotensin-converting enzyme inhibitor was dis-
continued during a prior hospitalization in 18 patients, in
the course of outpatient treatment preceding hospitalization
for 24 patients (12 by a primary care provider and 12 by an
outpatient cardiologist), and during the current hospitaliza-
tion for 32 patients. The location of angiotensin-converting
enzyme inhibitor discontinuation was not available for 10
patients.
Baseline characteristics of patients with circulatory-renal
limitations to angiotensin-converting enzyme inhibitors.
The CRLimit patients had more than twice the duration of
known HF as patients still taking angiotensin-converting
enzyme inhibitors (5 vs. 2 years, p  0.009). The pread-
mission clinical class was III or IV in 82%, versus only 50%
in patients discharged on angiotensin-converting enzyme
inhibitors. Other clinical descriptors of worse outcome in
this population included older age and higher prevalence of
ischemic etiology (Table 2). The CRLimit patients did not
differ significantly from the patients on angiotensin-
converting enzyme inhibitors in gender, race, left ventricular
ejection fraction, or prevalence of diabetes mellitus.
The systolic blood pressure on admission was 110 mm
Hg in patients on angiotensin-converting enzyme inhibitors
and 104 mm Hg in the CRLimit group (p  0.05). The
systolic blood pressure on discharge was 100 mm Hg in the
patients still on angiotensin-converting enzyme inhibitors
and 102 mm Hg in the CRLimit patients, 32 of whom had
their angiotensin-converting enzyme inhibitors discontin-
ued between admission and discharge. The admission and
discharge creatinine were 1.2 mg/dl in the patients on
angiotensin-converting enzyme inhibitors. In the CRLimit
group, creatinine was 2.45 mg/dl at admission and 2.0
mg/dl at discharge. Of patients discharged on angiotensin-
converting enzyme inhibitors, 41% had an initial creatinine
1.2 mg/dl, compared with 81% of the CRLimit patients.
The highest recorded creatinine during hospitalization was
1.5 mg/dl in the patients on angiotensin-converting enzyme
inhibitor and 3.0 mg/dl in the CRLimit group (all differ-
ences p value  0.0001). The admission sodium was 138
mmol/l in the patients on angiotensin-converting enzyme
inhibitors and 135 mmol/l in the CRLimit group (p 
0.002). The lowest recorded sodium during hospitalization
was 135 mmol/l in the patients on angiotensin-converting
enzyme inhibitors and 132 mmol/l in the CRLimit group (p
 0.002). The discharge sodium concentration was 138
mmol/l in patients on angiotensin-converting enzyme in-
hibitors and 136.5 mmol/l in patients with CRLimit (p 
0.15).
The discharge potassium was 4.2 mEq/l in the patients
on angiotensin-converting enzyme inhibitors and 4.1 mEq/l
in the CRLimit group (p  0.28). The highest recorded
potassium during hospitalization was 4.8 mmol/l in patients
on angiotensin-converting enzyme inhibitors and 5.1
Table 2. Baseline Characteristics of Patients With Heart Failure Treated With and
Without ACEIs
Baseline Characteristic










Age (yrs) 55 (42–65) 60 (53–68) 64 (55–72)* 0.006
Male 70 80 37 0.18
African American 13% 5% 8% 0.14
Ischemic cardiomyopathy 43 65.0 50.0 0.004
Duration of heart failure (yrs) 2 (0.5–7) 5 (2–8) 3.5 (2–10)* 0.009
Ejection fraction (%) 22.5 (15–28) 20 (15–26.3) 20 (15–29) 0.45
NYHA class III to IV 50 82 67 0.00002
Diabetes mellitus 34 38 29 0.64
Systolic blood pressure (mm Hg) 110 (100–123) 103.5 (90–122) 105 (92–127) 0.05
Paced ECG rhythm 12 28 13 0.03
Creatinine (mg/dl) 1.2 (1.0–1.5) 2.5 (1.8–3.2) 1.4 (1.1–2.0) 0.0001
Sodium (mmol/l) 138 (136–140) 135 (130–139) 138 (136–140) 0.002
Potassium (mmol/l) 4.2 (3.9–4.5) 4.1 (3.7–4.5) 4.0 (3.7–4.3) 0.28
*Compared with patients on ACEI, the No ACEI-due to cough/other adverse effects were significantly older with intermediate
duration of heart failure.
ACEI  angiotensin-converting enzyme inhibitors; CRLimit  circulatory-renal limitations; ECG  electrocardiogram;
NYHA  New York Heart Association.











Symptomatic hypotension 16.3 (14)
Renal insufficiency 45.3 (39)
Sympomatic hypotension and renal insufficiency 5.8 (5)
Hyperkalemia 2.3 (2)
Unknown 2.3 (2)
*Because one patient had both taste disturbance and hypotension, n  87.
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mmol/l in patients with CRLimit (p  0.12). The two
patients with history of hyperkalemia had peak potassium
levels of 5.6 and 8.3 mEq/l documented during this hospi-
talization.
Discharge therapies. Compared with patients on angiotensin-
converting enzyme inhibitors, half as many CRLimit pa-
tients were on beta-blockers, and almost four times as many
were receiving thiazide diuretics in addition to loop diuretics
at discharge (Table 3). One-quarter of the CRLimit group
was discharged on home intravenous inotropic therapy. The
median daily dose of loop diuretics was similarly high in
both groups.
The cough-other group. The relatively small group with
other side effects limiting angiotensin-converting enzyme
inhibitors (cough-other group, n  24) resembled the
patients on angiotensin-converting enzyme inhibitors in
most clinical characteristics (Table 1). The cough-other
patients were significantly older than patients on
angiotensin-converting enzyme inhibitors and 62.5% were
women. The cough-other group had similar use of beta-
blockers, and no patients were discharged on home intra-
venous inotropic infusions. Angiotensin-receptor blocker
use was 75%.
Survival. During a median 8.5-month follow-up, death
occurred in 22% of patients on angiotensin-converting
enzyme inhibitors and 57% of the CRLimit patients (p 
0.0001). The rate of heart transplantation was 4.6% in the
patients on angiotensin-converting enzyme inhibitors and
6.7% in the CRLimit group (p  0.51), with rates of
LVAD placement 2.3% and 3.3%. The combined event rate
(death, heart transplantation, or LVAD placement) was
27% in patients on angiotensin-converting enzyme inhibi-
tors and 62% in the CRLimit patients (p  0.0001).
Subsequent analyses are for the combined end point of
death, heart transplantation, and LVAD placement. The
estimated proportion of patients without an event at six
months was 82 3% for patients on angiotensin-converting
enzyme inhibitors and 44 7% for the CRLimit patients (p
 0.0001; Fig. 1). The increased event rate in the CRLimit
patients is evident by the end of the first month.
Of the 60 patients in the CRLimit group, 14 were
discharged on intravenous inotropic therapy. The combined
event rate was 86% in CRLimit patients discharged on IV
inotropic therapy and 54% in CRLimit not on IV inotropic
therapy (p  0.0002).
The combined event rate for the cough-other group was
45.8% (p  0.0001 compared with patients on angiotensin-
converting enzyme inhibitors). The estimated proportion of
patients without an event at six months was 55  11% (p 
0.006 compared with patients on angiotensin-converting
enzyme inhibitors).
A multiple variable proportional hazards model was
developed to assess the risk of having an event for CRLimit
relative to angiotensin-converting enzyme inhibitors while
controlling for potentially confounding factors known to
influence outcome: age, ejection fraction, ischemic cardio-
myopathy, systolic blood pressure, creatinine, and sodium
(23–32). The final parsimonious model retained sodium,
systolic blood pressure, and age in addition to the
angiotensin-converting enzyme inhibitor grouping. The
hazard ratio for CRLimit relative to angiotensin-converting
enzyme inhibitors while controlling for these factors was 2.8
(95% confidence interval [1.8, 4.4], p  0.0001).
DISCUSSION
This study demonstrates that 33% of patients hospitalized
on a HF referral service were discharged without prescrip-
tion of angiotensin-converting enzyme inhibitor therapy,
with documentation of reasons for non-angiotensin-
converting enzyme inhibitor use after prior angiotensin-
converting enzyme inhibitor therapy explicitly available in
all but 2% of patients. The 23% of patients who developed
CRLimit to angiotensin-converting enzyme inhibitor use
had more advanced disease in duration and symptom
severity, with lower blood pressure and serum sodium, and
worse renal function, when compared with patients still
taking angiotensin-converting enzyme inhibitors or the
smaller group not taking angiotensin-converting enzyme
inhibitors because of angioedema or intolerable cough. The
development of perceived CRLimit to angiotensin-
converting enzyme inhibitors identified a population with
high early mortality.
Evolution of population with limitations to angiotensin-
converting enzyme inhibitor use. Many studies have in-
vestigated the rates of angiotensin-converting enzyme in-
hibitor administration in patients with HF (7–14). Early
studies noted that 24% to 86% of patients with left ventric-
ular systolic dysfunction were on angiotensin-converting
enzyme inhibitors, with low rates attributed to delayed
penetration of guidelines regarding angiotensin-converting
enzyme inhibitor therapy into practice. In the mid 1990s,
Table 3. Discharge Medications in Relation to ACEI Use
or CRLimit
Discharge Medication
Percent of Patients or Median












(mg; n  156)
160 (100–160) 160 (120–160) 0.28
Torsemide dose
(mg; n  53)
200 (100–200) 200 (100–400) 0.21
Thiazide diuretics 7 23 0.001
Nitrates 48 68 0.007
Hydralazine 4 43 0.0001
Spironolactone 26 33 0.32
Digoxin 62 43 0.01
Intravenous inotropes 0 23 0.0001
Abbreviations as in Table 2.
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the SPICE registry examined 9,280 patients from North
American and European sites (33). Angiotensin-converting
enzyme inhibitors were not prescribed in 20% of patients,
because of cough or angioedema in 9.4% of patients and
possible circulatory or renal limitations in 9% of patients.
Bart et al. (34) examined data from a similar period and
found that of 242 patients admitted to a tertiary care
medical center with HF, 24% were not on angiotensin-
converting enzyme inhibitors, among whom 42.1% exhib-
ited circulatory or renal limitations. The lower prevalence of
angiotensin-converting enzyme inhibitor nonuse and the
lower rate of CRLimit in these studies may reflect lower
disease acuity in their population, in which the ejection
fraction was 27% compared with 22% in this study, and only
9% of their population had NYHA class IV HF at baseline.
The current demonstration of the higher rate of 33% not
taking angiotensin-converting enzyme inhibitors is in pa-
tients with more advanced HF. In this study, beginning
after 2000, all patients had previously been tried on
angiotensin-converting enzyme inhibitors, and the reason
for non-angiotensin-converting enzyme inhibitor use was
documented in 98% of patients. Compared with spontane-
ous documentation in only 65% in the earlier study from
eight years ago, the higher rate may reflect a heightened
awareness of both the trials of angiotensin-converting en-
zyme inhibitor therapy and potential scrutiny of prescribing
performance.
Characterization of patients with CRLimit to angiotensin-
converting enzyme inhibitors. The phenomenon of
CRLimit to angiotensin-converting enzyme inhibitor use is
becoming more obvious as the experience with HF length-
ens. These patients had an average disease duration of five
years, compared with two years in patients still tolerating
angiotensin-converting enzyme inhibitors. The success of
early therapy to delay disease progression and prevent
untimely sudden death is allowing more patients to advance
to the stage of disease beyond current therapies and guide-
lines. In addition to the longer duration of disease, patients
with CRLimit to angiotensin-converting enzyme inhibitor
use demonstrated other baseline characteristics of greater
disease severity. These patients had almost triple the inci-
dence of class IIIB to IV HF symptoms characterized before
the events leading to hospitalization, with higher mortality
expected (23). Renal insufficiency with or without symp-
tomatic hypotension accounted for the most common
CRLimit, and higher creatinine has recently been shown in
multiple studies to be a very strong predictor of worse
outcome, even for modest elevations (24–27). Long recog-
nized to be a predictor of worse outcome, low serum sodium
has also been described previously as associated with greater
limitation to angiotensin-converting enzyme inhibitor ini-
tiation (29). The other major limitation of angiotensin-
converting enzyme inhibitor use, symptomatic hypotension,
reflects lower systolic blood pressure, a robust predictor of
Figure 1. Kaplan-Meier plot of survival without left ventricular assist device or transplant for 173 patients on angiotensin-converting enzyme inhibitors
(ACEI), 45 patients with circulatory-renal limitations (CRLimit) not on intravenous (IV) inotropes, and 14 patients with CRLimit on IV inotropes.
Patients on angiotensin-converting enzyme inhibitors had significantly longer survival time than patients with CRLimit (p  0.0001). CRLimit patients
who did not receive IV inotropes had significantly longer survival times than CRLimit patients who received IV inotropes (p  0.002). The numbers of
patients remaining at three-month intervals up to 24 months are noted on the plot.
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worse outcome in recent trials in which it has been reported
(29,30).
Other baseline factors predicting higher risk in the
population with circulatory renal limitations to angiotensin-
converting enzyme inhibitor use are greater age (30) and a
higher incidence of ischemic cardiomyopathy (31). Left
ventricular ejection fraction was not different, and has not
been a strong predictor once severely reduced (32). Paced
rhythm has been associated with progression of hemody-
namic decompensation, and was twice as common in the
CRLimit group (35).
The discharge therapies of the CRLimit patients are also
consistent with an unstable population of advanced HF.
The lower rate of beta-blocker use confirms either the
perception or recognition of inability to tolerate inhibition
of the sympathetic nervous system. The high median daily
dose of loop diuretics and a higher rate of thiazide diuretic
use imply more refractory fluid retention. The most impor-
tant medication difference may be the frequency, previously
unappreciated at the investigating center, of intravenous
inotropic infusions to allow discharge of 23% of patients
unable to tolerate angiotensin-converting enzyme inhibi-
tors. Because intravenous inotropic therapy is generally
continued only to support blood pressure for ambulation or
renal function to relieve congestive symptoms, it was not
used in any patients able to tolerate angiotensin-converting
enzyme inhibitors or angiotensin receptor antagonists, as
the program policy was to try all other options, including
discontinuation of these agents, before accepting inotropic
dependence.
Outcomes of patients with CRLimit to angiotensin-
converting enzyme inhibitors. Despite mean follow-up of
only 8.5 months, the CRLimit patients demonstrated an
almost 2.5-fold higher incidence of death, ventricular as-
sist device placement, and transplantation. Whereas
angiotensin-converting enzyme inhibitor intolerance may
have influenced decisions regarding mechanical support and
transplantation, these accounted for only six of the 37
events. Multiple factors may contribute to the 50%
mortality of the angiotensin-converting enzyme inhibitor
group within six months. Baseline characteristics would
have predicted that the CRLimit group would have mor-
tality in excess of the patients on angiotensin-converting
enzyme inhibitors, regardless of treatment. To the extent
possible with this limited population, multivariate analysis
supports an independent contribution of the descriptor of
CRLimit to higher mortality, even when adjusting for age,
presence of coronary artery disease, ejection fraction, systolic
blood pressure, sodium, and creatinine. In ways only partly
reflected by previous predictors, these patients may not
tolerate angiotensin-converting enzyme inhibitors because
of more severe underlying cardiac and renal compromise,
leading to greater dependence on the renin-angiotensin
system for immediate support of blood pressure and renal
perfusion.
The absence of benefit from angiotensin-converting en-
zyme inhibitor therapy itself may contribute to higher
mortality. The mortality for patients with idiosyncratic
rather than CRLimit to angiotensin-converting enzyme
inhibitors was higher than for patients on angiotensin-
converting enzyme inhibitors, suggesting adverse impact of
a non-angiotensin-converting enzyme inhibitor regimen,
even with the prescription of angiotensin-II antagonists in
most of these patients. The nature and degree of circulatory
and renal contraindications to angiotensin-converting en-
zyme inhibitor use are controversial. All patients had pre-
viously been receiving chronic angiotensin-converting en-
zyme inhibitor therapy. The strong commitment to
angiotensin-converting enzyme inhibitor use by the HF care
team in this study led to repeated attempts to use
angiotensin-converting enzyme inhibitors by modifying
other components of the regimen. However, without rigid
prospective definitions, it is not possible to determine
whether other solutions could be found without discontinu-
ing angiotensin-converting enzyme inhibitors. Survival
might have been improved if angiotensin-converting en-
zyme inhibitors were continued with less physician concern
for symptomatic hypotension, or if patients were maintained
on angiotensin-converting enzyme inhibitors at the cost of
a higher volume status with increased congestive symptoms
but more stable renal function. These decisions require
individualization of priorities, which for some patients favor
symptom relief over survival when severe symptoms limit
comfort at rest.
The use of chronic outpatient inotropic therapy in 23% of
the CRLimit patients itself was a likely factor in the
increased mortality of the overall CRLimit group. Mortality
in patients receiving continuous intravenous inotropic
agents has been reported as 30% to 50% by six months, as
observed in this study (29).
Study limitations. Because this study focuses on patients
treated at a center specializing in HF, the results may not
reflect those of routine clinical practice. However, this is the
ideal population in which to begin study of the CRLimit
population because of the familiarity of HF/transplant
referral programs with the importance of angiotensin-
converting enzyme inhibitors and with the low blood
pressures and renal dysfunction in the more advanced stages
of disease. Because angiotensin-converting enzyme inhibi-
tor titration and documentation were not performed in
anticipation of this review, there was no standard definition
among differing HF physicians, but there was thus an
opportunity to determine the adequacy of routine sponta-
neous documentation. This study had only 8.5 months of
mean follow-up. Nevertheless, even in this short time
period, 50% of the CRLimit patients had died.
Conclusions. Patients hospitalized with advanced HF who
are discharged without angiotensin-converting enzyme in-
hibitors because of perceived CRLimit have 50% six-
month mortality that may reflect not only greater duration
and severity of HF, but also the paucity of information
regarding best therapy. Greater recognition and focus on
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therapies for the population of patients with CRLimit to
angiotensin-converting enzyme inhibitor use are critical as
the duration of HF survival increases and more patients face
these limitations.
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